Table 3 Baseline features of EGPA patients with and without CNS involvement
| Characteristics | With CNS involvement (n = 19) | Without CNS involvement (n = 91) | P value |
|---|---|---|---|
| Demographics | |||
| Age (year) | 51.7 ± 11.56 | 43.7 ± 13.78 | 0.019* |
| Gender (male/female, number) | 10/9 | 51/40 | 0.490 |
|
Time from allergy to EGPA diagnosis (month) | 48 (5, 115) | 24 (5, 60) | 0.314 |
| Disease duration (month) | 11 (4, 39) | 5 (2, 14) | 0.082 |
| Time from initial symptoms to vasculitis (month) | 21 (2, 54) | 7 (0, 36) | 0.337 |
| Clinical manifestation, n (%) | |||
| Weight loss | 6 (31.6) | 35 (38.5) | 0.573 |
| Fever | 11 (57.9) | 34 (37.4) | 0.098 |
| Arthritis | 4 (21.1) | 13 (14.3) | 0.489 |
| Myalgia | 6 (31.6) | 16 (17.6) | 0.207 |
| Allergic rhinitis | 6 (31.6) | 34 (37.4) | 0.634 |
| Severe asthma | 13 (68.4) | 72 (79.1) | 0.368 |
| Cutaneous vasculitis | 11 (57.9) | 48 (52.7) | 0.682 |
| Renal involvement | 4 (21.1) | 24 (26.4) | 0.776 |
| Digestive tract involvement | 10 (52.6) | 26 (28.6) | 0.042* |
| Peripheral neuropathy | 11 (57.9) | 40 (44.0) | 0.268 |
| Cardiac involvement | 5 (26.3) | 35 (38.5) | 0.317 |
| Ear involvement | 4 (21.1) | 10 (11.0) | 0.258 |
| Sinusitis | 11 (57.9) | 53 (58.2) | 0.978 |
| Laboratory examination | |||
| Eos count (109/L) | 4.1 (1.5,5.6) | 2.6 (1.4,7.6) | 0.770 |
| Eos% | 37.2 (11.8,50.0) | 28.6 (17.1,45.7) | 0.483 |
| ESR (mm/1 h) | 27 (9,40) | 32 (14,54) | 0.461 |
| CRP (mg/L) | 10.84 (5.34,39.77) | 21.70 (4.54,63.85) | 0.623 |
| RF (IU/mL) | 21.7 (7.0,90.1) | 25.0 (10.0,90.4) | 0.651 |
| MPO-ANCA, n (%) | 3 (15.8) | 12 (13.2) | 0.721 |
| PR3-ANCA, n (%) | 1 (5.3) | 1 (1.1) | 0.317 |
| Biopsy-proven vasculitis | 4 (21.1) | 10 (11.0) | 0.258 |
| Granuloma, n (%) | 1 (5.3) | 5 (5.5) | 1.000 |
| Clinical score | |||
| BVAS | 16 (14,22) | 14 (10,19) | 0.103 |
| FFS ≥ 1, n (%) | 16 (84.2) | 65 (71.4) | 0.250 |